| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.36 | 6e-11 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.35 | 1e-09 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.28 | 3e-09 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.26 | 3e-08 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |